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a b s t r a c t
The effectiveness of current treatment for age related macular degeneration (AMD) by targeting one
molecule is limited due to its multifactorial nature and heterogeneous pathologies. Treatment strategy to
target multiple signaling pathways or pathological components in AMD pathogenesis is under
investigation for better clinical outcome. Inhibition of the redox function of apurinic endonuclease 1/
redox factor-1 (APE1) was found to suppress endothelial angiogenesis and promote neuronal cell
recovery, thereby may serve as a potential treatment for AMD. In the current study, we for the ﬁrst time
have found that a speciﬁc inhibitor of APE1 redox function by a small molecule compound E3330
regulates retinal pigment epithelium (RPEs) cell response to oxidative stress. E3330 signiﬁcantly blocked
sub-lethal doses of oxidized low density lipoprotein (oxLDL) induced proliferation decline and
senescence advancement of RPEs. At the same time, E3330 remarkably decreased the accumulation of
intracellular reactive oxygen species (ROS) and down-regulated the productions of monocyte chemoat-
tractant protein-1 (MCP-1) and vascular endothelial growth factor (VEGF), as well as attenuated the level
of nuclear factor-κB (NF-κB) p65 in RPEs. A panel of stress and toxicity responsive transcription factors
that were signiﬁcantly upregulated by oxLDL was restored by E3330, including Nrf2/Nrf1, p53, NF-κB,
HIF1, CBF/NF-Y/YY1, and MTF-1. Further, a single intravitreal injection of E3330 effectively reduced the
progression of laser-induced choroidal neovascularization (CNV) in mouse eyes. These data revealed that
E3330 effectively rescued RPEs from oxidative stress induced senescence and dysfunctions in multiple
aspects in vitro, and attenuated laser-induced damages to RPE–Bruch's membrane complex in vivo.
Together with its previously established anti-angiogenic and neuroprotection beneﬁts, E3330 is
implicated for potential use for AMD treatment.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Age-related macular degeneration (AMD) is the leading cause of
central vision loss in the elderly in developed world, and an
increasing public health problem due to population aging [1,2].
There are two forms of AMD, the dry form (or non-exudative;
atrophic) and the wet form (or exudative; neovascular). Currently
the most widely used therapies for AMD are limited to laser
photocoagulation and intravitreal anti-vascular endothelial growth
factor (VEGF) agents for wet AMD [3]. However, these treatments
have various limitations such as insufﬁcient effectiveness or
requirement of repetitive intravitreal injections [4–6]. In addition,
no treatment is approved so far for dry AMD which could develop
into irreversible vision loss as severe as neovascular AMD. Although
the mechanism of AMD is not fully understood, it is well known
that AMD affects different cell types in the retina with a broad
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spectrum of corresponding pathologies involving photoreceptor
and RPE degeneration caused by cumulative oxidative stress and
local inﬂammation, as well as endothelial cell activation and
angiogenesis (for in-depth review, see Refs. [7,8]). Therefore,
strategies targeting a single molecule are not sufﬁcient to control
the disease process. Agents that regulate multiple signaling path-
ways or multiple pathological components are more likely to
produce a greater therapeutic effect for AMD.
In the past decade, the reduction/oxidation (redox) regulation
function of apurinic endonuclease 1/redox factor-1 (APE1/Ref-1,
here referred to as APE1) has been studied for its extended
repertoire in controlling cellular response to oxidative stress.
APE1 has two major functions in mammalian cells: DNA repair
[9,10] and redox regulation of gene transcription [11–13]. The DNA
repair function of APE1 dominants the base excision repair path-
way that responsible for repairing DNA damaged by oxidative
stress, alkylating agents, and ionizing radiation [14]. Equally
important, the redox function of APE1 enhances the DNA binding
of numerous redox-sensitive transcription factors via reduction of
disulﬁde bonds [13,15,16]. APE1 thereby represents an interesting
therapeutic target in different mechanistic contexts. While the
DNA repair function was a underlying mechanism of resistance to
chemotherapy in various cancers [9], the redox function may serve
as a target for modulating cell stress response, proliferation,
angiogenesis, and processes such as inﬂammation.
Many stress responsive transcription factors including nuclear
factor-κB (NF-κB) [17], hypoxia inducible factor-1α (HIF-1α)
[10,18], cAMP response element binding protein (CREB) [19],
activator protein-1 (AP-1) [17,20], p53 [21], and others have been
reported to be activated by APE1 dependent redox activation.
Theoretically, speciﬁc inhibition of the APE1 redox function may
inﬂuence multiple signaling pathways and downstream molecules
that could lead to various pathologies, without affecting the
genomic integrity as long as the DNA repair function is left intact.
In fact, it is possible to precisely eliminate the redox function of
APE1 without interfering with its DNA repair function, because the
two functions of APE1 have distinctively independent domains
and mechanisms [10,22]. Previous studies have identiﬁed a small
molecule inhibitor, E3330 (also called APX3330) which is speciﬁc
to APE1 redox activity [10,23–26]. E3330 signiﬁcantly reduced the
transcriptional activities of NF-κB [25] and HIF-1α [10,18] in
various cancer cells and endothelial cells without affecting the
DNA repair function [10,25,27]. These factors and their down-
stream effectors have been closely associated with the etiology
and pathogenesis of AMD [5,6,28–32]. We have recently reported
that E3330 effectively suppressed retinochoroidal angiogenesis
[33,34] and reduced neuronal cell loss [35]. These evidences
indicate that E3330 may affect multiple signaling pathways and
rectify multiple pathologies relevant to AMD pathogenesis
through inhibition of APE1 redox function. However, the role of
APE1 redox activity in retinal pigment epithelium cells (RPEs) is
not known.
RPEs are highly specialized pigmented epithelium lining
between the neural retina and Bruch's membrane, that plays
critical roles in maintaining the homeostasis of retinal neurons
and choroid [36,37]. RPEs are subject to lifelong chronic oxidative
injury due to the constant exposure to light, a high level of
metabolic activity, and accumulation of oxidized lipoprotein com-
ponent in the cell [38,39]. Oxidative stress induced senescence and
dysfunction of the macular RPEs is believed to herald AMD [8,40].
This study focused on the role of E3330 in regulating RPE
responses to the oxidative stimulus elicited by oxidized low-
density lipoprotein (oxLDL) in vitro and laser-induced RPE–Bruch's
membrane damage in vivo. We found that speciﬁc inhibition of
APE1 redox activity with E3330 signiﬁcantly rescued human RPEs
from proliferation decline and senescence advancement induced
by oxLDL. These effects were associated with reduced intracellular
ROS, down-regulated secretion of monocyte chemoattractant
protein-1 (MCP-1) and VEGF, and suppressed nuclear accumula-
tion of NF-κB p65. The DNA binding activities of multiple redox-
sensitive transcription factors including Nrf2/Nrf1, p53, NF-κB,
HIF1, CBF/NF-Y/YY1, and MTF-1 were directly repressed by
E3330. A single intravitreal injection of E3330 markedly reduced
the laser-induced lesion size in RPE–Bruch's membrane complex
in mouse eyes. These ﬁndings suggest that E3330 holds great
therapeutic promise for AMD by rescuing RPEs from oxidative
stress in multiple aspects and reducing in vivo RPE–Bruch's
membrane complex damage. APE1 redox function could serve as
a potential therapeutic target in the management of AMD.
2. Results
2.1. E3330 blocks sub-lethal doses of oxLDL-induced proliferation
decline of RPEs
OxLDL has been widely used as an experimental stimulant to
induce pathological stresses in RPE cells and mimic oxidative
damages seen in AMD [41,42]. In a TUNEL assay to exclude the
potential cell toxicity induced by oxLDL, no signiﬁcant RPE
apoptosis was observed at the doses of less than 450 μg/mL oxLDL
(p40.05 when compared with the negative control group;
Fig. 1. Effects of oxLDL and E3330 on RPE apoptosis (A) and proliferation (B) in vitro. A, TUNEL assay of RPEs exposed to various doses of oxLDL. A negative control without
terminal transferase and a positive control with DNase I was included. All data points were normalized to the total number of the cells seeded in each well. OxLDL at or under
300 μg/mL did not induced signiﬁcant cell apoptosis when compared with the negative control group. Signiﬁcant apoptosis was only seen at 450 μg/mL and 600 μg/mL oxLDL
treated groups. Bars represent mean7SEM of three independent experiments. npo0.05 versus the negative control. B, MTS assay of RPE proliferation in response to 0, 50,
100, or 150 μg/mL oxLDL alone or combined with 30 μM E3330. All treatment groups were normalized to be a percentage of the control group. OxLDL inhibited the RPE
proliferation dose dependently. 30 μM E3330 remarkably reversed the suppression effect of 100 μg/mL and 150 μg/mL oxLDL on RPE proliferation, but had no effect on the
cell growth by itself. Bars represent mean7SEM of three independent experiments. npo0.05 versus the no treatment control.
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Fig. 1A). Notable apoptotic cells that accounted for 8.1170.87%
and 36.6276.18% of the total cells were found respectively when
450 μg/mL and 600 μg/mL oxLDL were applied (po0.05 when
compared with the negative control group; Fig. 1A). A DNase I
treated group was included as positive control which induced a
100% cell apoptosis. Based on these data, previous reports 33,34],
and our previous studies on retino-choroidal angiogenesis in vitro
and in vivo [33,43], we adopted a sub-lethal dose range of
20–50 μM E3330, mostly 30 μM, which do not induce signiﬁcant
apoptosis in ARPE-19 in the rest of the experiments of the study.
To investigate the effect of E3330 on oxLDL stressed RPEs, we
ﬁrst examined RPE cell proliferation using a MTS assay. The RPE
growth was inhibited in a dose-dependent manner by 0–150 μg/
mL oxLDL. While 50 μg/mL oxLDL showed minimal effect, both
100 and 150 μg/mL oxLDL exposure signiﬁcantly reduced the cell
viability by 18.22710.9% and 29.376.73%, respectively (po0.05
when compared with the control group; Fig. 1B). Concomitant
addition of 30 μM E3330 completely prevented the suppression by
100 μg/mL oxLDL and restored the cell viability to 10075.99% of
the control level (po0.05 when compared with 100 μg/mL oxLDL
challenged group; Fig. 1B). A partial proliferation restoration of
86.977.87% by E3330 was observed when the RPEs were chal-
lenged with a higher dosage of 150 μg/mL oxLDL (po0.05 when
compared with 150 μg/mL oxLDL challenged group; Fig. 1B).
Application of 30 μM E3330 alone did not affect the ARPE-19 cell
viability in the absence of oxLDL challenge (Fig. 1B).
2.2. E3330 protects RPEs from oxLDL-induced senescence-like
phenotype
RPE cell senescence is a biological aging process associated
with physiological decline of the cellular function, and a key
contributor to AMD [44]. Using a SA-β-gal assay, we examined
the cellular senescence status in ARPE-19 cells under the challenge
of various doses of oxLDL with or without the treatment of E3330.
As shown in Fig. 2, both 100 and 150 μg/mL oxLDL promoted
senescence-like phenotype in RPEs by increasing the SA-β-gal
stain (po0.05 when compared with the control group). Addition
of 30 μM E3330 signiﬁcantly abolished the increment of SA-β-gal
activity induced by oxLDL (po0.05 when compared with the same
dose of oxLDL challenged group; Fig. 2). Among all dosage groups,
it was striking that E3330 was able to divert the entire upsurge of
over 70% increase of SA-β-gal accumulation in RPEs challenged by
150 μg/mL oxLDL. E3330 alone or with 50 μg/ml oxLDL did not
affect the SA-β-gal level in RPEs. These results clearly show that
E3330 effectively protected RPEs from oxLDL-induced stress with-
out affecting the basal senescence-related function.
According to these above mentioned apoptosis, proliferation
and senescence phenotype assays, 150 μg/mL oxLDL was adopted
as a sub-lethal dose to challenge RPEs for all the subsequent
experiments.
2.3. E3330 reduces the accumulation of intracellular ROS, secretion
of MCP-1 and VEGF, and nuclear level of NF-κB p65 in oxLDL-
challenged RPEs
Accumulation of intracellular ROS is a major source of oxidative
stress in AMD [40,45]. 150 μg/mL oxLDL signiﬁcantly increased the
intracellular ROS in RPEs by 20.2378.03% (po0.05 when com-
pared with the control group; Fig. 3A). This elevated intracellular
ROS was eliminated by 30 μM E3330 (po0.05 when compared
with 150 μg/mL oxLDL treated group; Fig. 3A). This is an interest-
ing ﬁnding that may at least partly explain the protective effect of
E3330 on oxLDL stressed RPEs.
RPEs derived MCP-1 [46], VEGF [47] and ApoE [48,49] are
critical contributors to local inﬂammation and angiogenesis in the
development of AMD. Co-treatment of E3330 remarkably elimi-
nated the striking upsurge secretion of both MCP-1 and VEGF
stimulated by oxLDL (po0.01 and po0.05 respectively when
compared with 150 μg/mL oxLDL challenged group; Fig. 3B and
C). In addition, 30 μM E3330 signiﬁcantly decreased MCP-1
production by 40% in the unchallenged RPEs (po0.01; Fig. 3B),
but did not affect much of the basal VEGF secretion from RPEs
(Fig. 3C). However, the increase of ApoE production by oxLDL was
not altered by the addition of 30 μM E3330 (Fig. 3D).
Several studies have reported that E3330 inhibits NF-κB
mediated transcription via different mechanisms [25,50–53]. In
this study, 150 μg/mL oxLDL signiﬁcantly increased the NF-κB p65
level in RPE nucleus, which was prominently reduced by con-
comitant 30 μM E3330 (Fig. 3E). E3330 alone did not affect the
level of p65 in un-challenged RPE nucleus.
2.4. E3330 blocks the activation of multiple transcription factors
induced by oxLDL in RPEs
To identify the transcription factor(s) that the APE1 redox
inhibitor E3330 regulates, a reporter gene assay array containing
a set of ten known stress and toxicity responding genes in ten
different pathways was applied. ARPE-19 cells were exposed to
150 μg/mL oxLDL alone or with 30 μM E3330. OxLDL remarkably
upregulated all the ten transcriptional activities in RPEs (p-value
varies when compared with the control group; Fig. 4 and Table 1).
The presence of E3330 signiﬁcantly repressed seven of the ten
transcription factors that stimulated by oxLDL. When compared
with the oxLDL challenged groups, E3330 decreased the transcrip-
tional activities of Nrf2/Nrf1 (59.91710.53%, po0.01), p53
(59.3576.80%, po0.001), NF-κB (57.6678.06%, po0.05), HIF1
(62.05711.06%, po0.05), CBF/NF-Y/YY1 (44.2479.03%, po0.01),
MTF1 (80.12711.60%, po0.05), and HSF-1 (63.1872.95%,
po0.01) in RPEs. When compared with the un-treated control
groups, six of the seven transcription factors had their DNA
binding activities almost completely restored to the basal levels
by E3330 (p40.05 when compared with the control group; Fig. 4
and Table 1), with the exception of HSF1. Though HSF1 of heat
shock pathway and AhR in xenobiotic drug metabolism were also
markedly repressed by E3330, the end point levels of these two
transcription factors were still signiﬁcantly higher than that in the
control groups (both po0.05 when compared with the control
group). The rest two transcription factors, glucocorticoid receptor
and AP1, demonstrated a trend towards reduction by E3330 but
did not reach statistic signiﬁcant points (both p40.05 when
Fig. 2. SA-β-gal stain of senescence-like phenotype in RPEs exposed to oxLDL and/
or E3330. ARPE-19 cells were exposed to 0, 50, 100, or 150 μg/mL of oxLDL alone or
combined with 30 μM E3330 for 48 h. Both 100 and 150 μg/mL oxLDL remarkably
increased the SA-β-gal level in ARPE-19. The increments were completely abolished
by concomitant treatment of 30 μM E3330. E3330 alone did not alter the basal level
of the SA-β-gal accumulation. Bars represent mean7SEM of three independent
experiments. npo0.05 versus the control group.
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compared with 150 μg/mL oxLDL challenged group). The fold
change and corresponding p-value are summarized in Table 1.
These data clearly revealed that E3330 was able to restore multiple
signaling pathways that stimulated by oxLDL which in turn may
prevent a range of pathogenic responses in RPEs.
2.5. E3330 reduces laser-induced CNV lesion in mouse eyes
A laser-induced CNV model is a classic animal model of wet
AMD which is an ocular wound-healing response to damage of the
RPE–Bruch's membrane–choroidal complex [7]. We adopted this
model to determine the in vivo effect of E3330. A single intravitreal
injection of either E3330 or vehicle was given right after the laser
photocoagulation. The treatment dosage of 1 μL 200 μM E3330
was equivalent to a ﬁnal concentration of approximately 20 μM in
the retinochoroidal tissue. After 2 weeks survival, a remarkable
40% reduction of the laser-induced CNV size was found in E3330
treated eyes when compared with the control eye (Fig. 5 A, B).
Mean value of the CNV size treated by E3330 was 10,568 μm2
while that of vehicle control treated was 16,531 μm2. The differ-
ence was statistically signiﬁcant (n¼6; p¼0.0200). These results
are consistent with our previous ﬁnding that a single intravitreal
treatment of E3330 inhibited the retinal angiomatous proliferation
(RAP)-like neovascularization in Vldlr/ mice [33].
3. Discussion
Age-related macular degeneration (AMD) is a progressive dis-
ease encompassing multifactorial pathogenesis involving metabolic,
functional, genetic and environmental factors, and affecting multi-
ple components in the retina including photoreceptors, retinal
pigment epithelium (RPE), Bruch's membrane and choriocapillaries.
Current therapies still have limitations in effectively controlling
this complex disease. The oxidative stress induced degeneration and
dysfunction of macular RPEs are early and crucial changes
contributing to local drusogenesis, inﬂammation and neovascular-
ization [8,40]. Protecting RPEs from oxidative damage is thereby an
Fig. 3. The effects of oxLDL and E3330 on intracellular ROS accumulation, cytokines production, and nuclear level of NF-κB p65 in RPEs. A, intracellular ROS level in ARPE-19
cells was measured by a ﬂuorescent probe DCFH-DA and presented as relative ﬂuorescent unit (RFU). OxLDL signiﬁcantly increased the intracellular ROS, which was
effectively abolished by concomitant E3330. B-D, ELISA assay of MCP-1 (B), VEGF (C), and ApoE (D) protein in APRE-19 conditioned media. The secretion of all the three
proteins was prominently increased by oxLDL. Addition of E3330 effectively prevented oxLDL-induced MCP-1 and VEGF overproduction, but did not alter the level of ApoE.
E3330 alone also reduced the production of MCP-1, but did not affect the VEGF and ApoE levels in un-challenged ARPE-19 cells. E, a representative gel image of NF-κB p65
and internal control protein actin in ARPE-19 nuclear fraction. Bars represent mean7SEM of three independent experiments. npo0.05 versus the control group.
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essential consideration for AMD treatment. In this study, we
demonstrated for the ﬁrst time that speciﬁc inhibition of APE1
redox function with E3330 effectively protected RPEs from oxLDL-
induced impairment and reduced the area of laser-induced damage
in RPE–Bruch's–choroidal complex. Taken together with our pre-
vious ﬁndings that E3330 signiﬁcantly suppressed in vitro angio-
genesis of retinal and choroidal endothelial cells [33,34], and
reduced retinal neovascularization in vivo [33], these data strongly
suggest E3330 is a promising therapeutic agent for AMD by rescuing
RPE degeneration and dysfunction from oxidative stress and redu-
cing endothelial angiogenesis at the same time.
3.1. APE1 redox function and its role in the retina and choroid
The presence of APE1 in the retina and choroid has been
established due to its critical roles in mammalian cells. We have
Fig. 4. Dual-luciferase reporter gene assay of the stress responding transcription factors in RPEs. OxLDL exposure signiﬁcantly up-regulated all the tested transcriptional
activities. E3330 completely blocked the up surge of six transcription factors (Nrf2/Nrf1, p53, NF-κB, HIF1, CBF/NF-Y/YY1, and MTF1) and markedly attenuated the activities of
HSF1 and AhR pathways. Glucocorticoid receptor exhibited a trend of reduction by E3330, but results were not statistically signiﬁcant. Bars represent mean7SEM of three
independent experiments. npo0.05 versus the control group. #po0.05 versus the oxLDL challenged group.
Table 1
Fold changes of the reporter gene activities in ARPE-19 cells in response to oxLDL alone or combined with E3330.
Transcription factor Reporter gene activity fold change Pathway
oxLDL/Control p Value oxLDLþE3330/oxLDL p Value oxLDLþE3330/Control p Value
Nrf2/Nrf1 1.71 0.008 0.60 0.003 0.84 0.409 Antioxidant response
p53 1.70 0.001 0.59 0.000 0.82 0.130 DNA damage
NFκB 1.76 0.008 0.58 0.011 1.04 0.850 NFκB
HIF-1 1.65 0.012 0.63 0.021 1.08 0.658 Hypoxia
CBF/NF-Y/YY1 2.33 0.002 0.44 0.004 1.16 0.549 ER stress
MTF1 1.26 0.043 0.80 0.042 1.00 0.980 Heavy metal stress
HSF-1 1.59 0.000 0.63 0.002 1.22 0.024 Heat shock
Glucocorticoid Receptor (GR) 1.49 0.015 0.68 0.312 1.33 0.065 Glucocorticoid
AP-1 1.43 0.039 0.71 0.113 1.13 0.465 MAPK/JNK
AhR 1.65 0.004 0.61 0.094 1.36 0.047 Xenobiotic
OxLDL versus Con, 150 μg/mL oxLDL challenge versus vehicle control.
OxLDLþE3330 versus oxLDL, concomitant treatment of 150 μg/mL oxLDL plus 30 μM E3330 versus 150 μg/mL oxLDL challenge.
OxLDLþE3330 versus Con, concomitant treatment of 150 μg/mL oxLDL plus 30 μM E3330 versus vehicle control.
Y. Li et al. / Redox Biology 2 (2014) 485–494 489
reported high levels of APE1 in the neural retina, puriﬁed retinal
vascular endothelial cells (RVECs) and retinal pericytes in mice [33].
We also found abundant expression of APE1 in human ARPE-19,
RVECs and choroidal endothelial cells (CECs) [34]. Chiarini et al.
[54,55] demonstrated that APE1 was mainly located in the nuclear
of all retinal cells and positively associated with the retina cell
differentiation during postnatal development in rats. APE1 was
postulated to accomplishes both functions of DNA repair and
reductively activation of transcription factors in the nuclear [56].
In previous studies, the function of APE1 was evaluated by
approaches such as gene knockout [57,58], DNA antisense [59,60]
and siRNA [61]. While valid, these approaches are not suitable for
the current study as they affect the entire APE1 molecule regard-
less of its distinctive dual functions. The subsequent changes are
the mixture of multiple effects in which the speciﬁc role of APE1
redox activity cannot be depicted. In addition, such approaches
could lead to cell cycle arrest [58], cell death [61] and early
embryonic lethality [57]. Recent identiﬁcation of the novel small
molecule inhibitor that speciﬁcally suppresses APE1 redox func-
tion, namely E3330, makes it possible to investigate the redox
activity individually [11,16,23]. The speciﬁcity of E3330 has been
well documented by several studies. E3330-ﬁxed latex beads
speciﬁcally bind to APE1 protein [24], and E3330 effectively blocks
multiple redox sensitive transcription factors without interfering
with the DNA repair function of APE1 [10,23,25,26,51]. By using
E3330, we have previously reported that APE1 redox function was
required for retinal and choroidal angiogenesis [33,34], and
involved in neural tissue recovery after stroke in diabetic rats
[35]. These and our current ﬁndings in RPEs clearly indicate that
inhibition of APE1 redox function have multiple beneﬁcial effects
in the retinochoroidal region including anti-angiogenesis, anti-
inﬂammation and neural protection.
3.2. Inhibition of APE1 redox function rescued degeneration and
dysfunction of RPEs induced by oxidative stress
OxLDL is known as a major contributor of oxidative stress and
inﬂammation in AMD pathology. Previous studies showed that
oxLDL inhibits RPE viability, promotes RPE senescence and apop-
tosis in a dose dependent manner [42], and disrupts multiple
functions of RPE cells at sub-lethal dosages [42,62]. OxLDL-
stimulated intracellular accumulation of ROS plays an important
role in linking oxidative stimulus with early dysfunctions of RPEs
[40,45]. The biological effects of oxLDL are mainly mediated
through signaling pathways, especially via activation of transcrip-
tion factors such as NF-κB [41,63]. In this study, E3330 effectively
attenuated sub-lethal oxLDL induced viability decline and senes-
cence advancement of RPEs, at the same time blocked intracellular
accumulation of ROS in the cell. It is quite possible that these
events occurred through the suppression of multiple transcription
factors via inhibition of APE1 redox function, since the ROS
generation mediated by NADPH oxidase (Nox) was actually con-
trolled by transcription factors including NF-κB [64], HIF-1 [65]
and Nrf2 [66,67]. Intracellular ROS reduction may subsequently
relieve the cellular macromolecules such as DNA, proteins, and cell
membrane lipids from oxidative stress [40,68], and suppress the
ROS triggered “activation signals” and the cross talk between ROS
and redox-sensitive transcription factors such as NF-κB [69] and
HIF-1 [70]. These changes presented as the regain of RPE prolif-
eration and reduction of senescence-like phenotype in RPEs in our
study. The fact that we saw such a broad spectrum of effects by
E3330 on RPE functions strongly indicated that all of these aspects
were affected in various degrees.
By examining the production of MCP-1 and VEGF by RPEs, we
found that the inhibitory effect of E3330 was translated from
redox sensitive transcription factors to downstream effector mole-
cules capable of mediating chronic inﬂammation and angiogenesis
in the retina and choroid. These ﬁndings supported our previous
reports that intravitreal application of E3330 signiﬁcantly reduced
retinal and choroidal neovascularization in mice [33,34], as RPEs is
a considerable source of VEGF and MCP-1 in the retinochoroidal
tissue. ApoE [49], another AMD related molecule that synthesized
by RPEs, was minimally regulated by E3330. The transcriptional
regulation of ApoE gene expression is known to be cell-type
speciﬁc [71]. Ishida et al. reported that ApoE secretion by human
RPEs was transcriptionally regulated by ligands for nuclear hor-
mone receptors such as thyroid hormone receptor, liver X receptor
and retinoid X receptor [48]. While little is known so far about
APE1 redox regulation on these transcription factors, our data
indicated that oxLDL-induced ApoE production in RPEs was not
regulated by APE1 redox signals.
NF-κB is arguably the most studied transcription factor in the
pathogenesis of AMD. It is known NF-κB can be activated by
oxidative stress and regulates expressions of various pro-
inﬂammatory and pro-angiogenesis factors in RPEs, including
MCP-1, ICAM-1, ILs, and VEGF [28,41,72]. E3330 is able to suppress
the NF-κB activity through different mechanisms. For example,
Handa's team reported that E3330 inhibited the NF-κB DNA binding
through reversing the APE1-dependent reduction of Cys-62 residue
of p50, without affecting the IκB-α degradation and p65 transloca-
tion or phosphorylation in Jurkat cells [25,50]. Goto et al. showed
that E3330 impaired the nuclear translocation of NF-κB and
degradation of IκB-α in human peripheral monocytes [51]. The
differences noted in these reports are probably due to the usage of
different methodology and cell-speciﬁc differences. In the current
study, we examined the effect of E3330 on the nuclear level of NF-
κB p65 as nuclear localization is required for both APE1 and NF-κB
to accomplish their functions. We found E3330 markedly reduced
the nuclear accumulation of p65 protein, which was complied with
the inhibitory effect of E3330 on NF-κB DNA binding as is shown in
luciferase reporter gene assay. As other NF-κB proteins such as p50,
p52, RelB and cRel may also contribute to the transcriptional activity
of NF-κB in RPEs, additional experiments investigating the under-
lying mechanism are necessary.
Fig. 5. Single intravitreal injection of E3330 signiﬁcantly reduced laser-induced
CNV area in mouse eyes. Laser-induced CNV mice received a single intravitreal
injection of 1 μL of 200 μM E3330 (equivalent to intravitreal centration of
approximately 20 μM) in one eye and 1 μL BSS in the fellow eye immediately
following laser photocoagulation of RPE–Bruch's membrane. Isolectin stain was
performed after two weeks survival. (A and B) Representative images of isolectin
staining of CNV lesions. The area of CNV lesion in E3330 treated eye (B) was
obviously reduced when compared to BSS treated eyes (A). Scale bar: 100 μm.
(C) Quantitative analysis showed that the mean value of the CNV area treated by
E3330 was signiﬁcantly lower than that of vehicle control treated (n¼6;
p¼0.0200).
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3.3. Inhibition of APE1 redox function represses multiple stress-
responding transcription factors in RPEs
We have provided data in this study that E3330 signiﬁcantly
repressed the oxLDL-induced stimulation of at least six (Nrf2/Nrf1,
p53, NFκB, HIF1, CBF/NF-Y/YY1, and MTF1) transcription factors in
RPEs. Some of these transcription factors are directly implicated in
dry and/or wet AMD pathogenesis. Nrf2/Nrf1 is critical in retinal
antioxidant and detoxiﬁcation responses [73,74]. p53 stimulates
RPE apoptosis and cell cycle arrest [75,76]. NF-κB regulates the
production of pro-inﬂammatory factors and growth factors in
several stress sceneries including immune reactions, inﬂammation
and hypoxia in RPEs [28,29,77]. HIF1 mainly controls the VEGF
production induced by hypoxia [30]. It is noteworthy that although
the effect of E3330 is quit potent affecting multiple transcription
factors, at the given dose it only blocked the aberrantly up-
regulated transcriptional activities and brought them back down
to the levels comparable to their basal activities. These data
demonstrated that targeting APE1 redox activity could modulate
multiple signaling pathways closely related to AMD pathogenesis
and may achieve a greater therapeutic effect than any mono-target
therapies, without causing side effects from complete inhibition of
any given transcription factor.
3.4. APE1 redox function in inhibiting choroidal neovascularization
Laser-induced CNV is an wound-healing response to the
damage of RPE–Bruch's–choroidal complex [7]. The growth of
CNV is largely promoted and directed by RPE derived signals,
typically increased expression of VEGF via HIF-1 [78] and NF-κB
[72] signaling pathways, and MCP-1 via NF-κB pathway [28,79,80].
Therefore, the ﬁnding that intravitreal E3330 signiﬁcantly reduced
the laser-induced CNV in mouse eyes can be at least partly
attribute to the attenuated transcription activities of NF-κB and
HIF-1, as well as decreased production of MCP-1 and VEGF in RPEs
by E3330. However, E3330 also directly inhibits the angiogenic
activities of endothelial cells [33,34]. Due to the nature of laser-
induced CNV animal model, it is difﬁcult for us to distinguish
whether the actual effect of APE1 redox inhibition is from CEC or
RPE or both at this point. Further studies are underway for a more
comprehensive understanding of this issue.
In summary, we demonstrated that speciﬁc inhibition of APE1
redox activity with E3330 signiﬁcantly protected RPEs from
oxLDL-induced stresses and reduced laser-induced CNV in mouse
eyes. This effect was mediated by inhibiting ROS generation,
repressing multiple redox sensitive transcription factors, and
preventing upsurge of downstream pro-inﬂammatory and pro-
angiogenic molecules. These ﬁndings in RPEs along with our
previous reports of the anti-angiogenenic effect on retinochoroidal
endothelial cells [33,34,79] suggested that speciﬁc inhibition of
APE1 redox activity with E3330 could be a promising therapeutic
strategy for both dry and wet AMD by targeting multiple signaling
pathways in the context of hypoxia, choronic inﬂammation, and
angiogenesis. Further studies are necessary for a better under-
standing of the underlying mechanisms for this novel AMD
treatment.
4. Materials and methods
4.1. Materials
A RPE cell line from adult human, ARPE-19 (American Type
Culture Collection, Manassas, VA), was cultured in DMEM (Gibcos
Life Technologies, Grand Island, NY) supplemented with 10% FBS in
a 37 1C incubator with 5% CO2. ARPE-19 cells near conﬂuence were
resuspended by 0.25% Trypsin–EDTA (Gibcos Life Technologies,
Grand Island, NY) and used for sub-culture and various assays.
OxLDL, a widely used experimental paradigm for AMD [41,42],
was commercially purchased (Kalen Biomedical, Montgonery
Village, MD) and used to induce pathological stress in ARPE
-19 cells. E3330[(2E)-3-[5-2,3-dimethoxy-6-methyl-1,4-benzoqui-
noyl)]-2-nonyl-2-propenoic acid] was ﬁrst dissolved in dimethyl-
sulphoxide (DMSO, Sigma-Aldrich Co. Saint Louis, MO) at a
concentration of 20 mM, then diluted in culture medium to reach
various end point doses. The ﬁnal concentration of DMSO in the
medium did not exceed 0.01% (vol/vol). A dose of 30 μM of E3330
was applied throughout this study according to our previous
observation that 20–50 μM E3330 signiﬁcantly reduced retino-
choroidal angiogenesis in vitro and in vivo in the absence of dose-
related adverse effects [33,34], as well as our pilot dose-response
experiments in ARPE-19 cells. Cells were treated with vehicle
control, 30 μM E3330 alone or in combination with various doses
of oxLDL. A vehicle control with matched concentration of DMSO
without E3330 was routinely included in each experiment.
4.2. Cell apoptosis and proliferation assay
The effects of oxLDL and/or E3330 on RPE apoptosis and
proliferation was measured by a TdT mediated dUTP-ﬂuorescein
nick end-labeling (TUNEL) Reaction kit (In Situ Cell Death Detec-
tion Kit, Roche, Indianapolis, IN) and a CellTiter 96s AQueous One
Solution Reagent (Promega Corporation, Madison, WI) respec-
tively. ARPE-19 cells were seeded in 96-well plates at 2000 cell/
well and exposed to various doses of oxLDL alone or combined
with 30 μM E3330 for 48 h in a 37 1C incubator. These assays were
performed following the manufacture's protocol.
4.3. Cell senescence associated β-gal (SA-β-gal) assay
A cellular senescence assay kit (Cell Biolabs, San Diego, CA) was
used to determine the effect of E3330 on senescence-like pheno-
type of RPEs. ARPE-19 cells seeded at 2000 cells/well in 96-well
plates were exposed to oxLDL alone or combined with 30 μM
E3330 for 48 h in a 37 1C incubator. After centrifugation, 50 μL of
the supernatant of each sample was collected and immediately
incubated with 50 μL of freshly prepared ﬂuorometric substrate
for 2 h at 37 1C in darkness. The ﬂuorescent intensity of each
reaction mixture was determined by a SpectraMax M2e microplate
reader (Molecular Devices LLC, Sunnyvale, CA) at an excitation
wavelength of 360 nm and emission wavelength of 465 nm.
4.4. Intracellular ROS measurement
The intracellular ROS accumulation in RPEs was measured by
2', 7'-dichlorodihydro ﬂuorescin diacetate (DCFH-DA) using an
intracellular ROS assay kit (Cell Biolabs, San Diego, CA). ARPE-19
cells were pre-loaded with DCFH-DA by exposure to freshly
prepared 100 mM DCFH-DA in the culture medium for 30 min in
a 37 1C incubator. Then the DCFH-DA loaded cells were treated
with 150 μg/mL oxLDL alone or combined with 30 μM E3330 for
48 h. DCFH ﬂuorescence of the cell lysate was measured with
excitation and emission settings of 485 and 530 nm by a micro-
plate reader.
4.5. ELISA assay
The protein concentrations of MCP-1, VEGF and ApoE in the
conditioned medium of ARPE-19 cells were determined using
commercially available ELISA kits (R&D Systems, Minneapolis,
MN) following the manufacturer's instructions.
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4.6. Western blot
ARPE-19 cells were treated with 150 μg/mL oxLDL or 30 μM
E3330 alone or in combination for 48 h. Nuclear proteins were
extracted from ARPE-19 cells with a NE-PER Nuclear and Cyto-
plasmic Extraction Kit (Thermo Scientiﬁc, Rockford, IL) according
to the manufacture's instruction. The nuclear proteins were
separated by SDS-PAGE, and western blot was performed with
an anti-NF-κB p65 antibody (Cell Signaling Technology, Beverly,
MA) overnight at 4 1C. β-actin (Abcam, Cambridge, MA) was used
as a loading control. Quantitative densitometry analysis was
performed using an Image Lab™ Software (Bio-Rad, Hercules,
CA). The ratio of NF-κB p65 and β-actin was presented.
4.7. Luciferase reporter gene assay
The reporter gene assay was performed using a Cignal Finder
Stress & Toxicity 10-Pathway Reporter Array (Qiagen-SABios-
ciences, Valencia, CA). Brieﬂy, ARPE-19 cells were exposed to
150 μg/mL oxLDL alone or combined with 30 μM E3330 for 48 h.
The treated cells at 40–60% conﬂuence were transfected with
equal amounts of the mixed ﬁreﬂy luciferase (Fluc) and Renilla
luciferase (Rluc) reporter vector for 24 h using Attractene transfec-
tion reagent (Qiagen, Valencia, CA). Then the fresh medium was
added and incubated for another 6 h. Fluc and Rluc expressions
were detected using a Dual-Luciferase Reporter Assay System
(Promega Corporation, Madison, WI) with a Luminometer Spec-
traMax M2e according to the manufacturer's instruction. The
transcription activities, as indicated by the Fluc reading, were
normalized to Rluc. The ratio of Fluc and Rluc was divided by the
ratio of the promoterless positive control luciferase to determine
the fold change.
4.8. Animals
Male wild-type C57BL/6J mice of 6–8 weeks were used in the
in vivo studies. Animals were housed on a 12-h light-dark cycle
with free access to food and water. All procedures were performed
with strict adherence to the guidelines for animal care and
experimentation prepared by the Association for Research in
Vision and Ophthalmology and approved by the Henry Ford Health
System Institutional Animal Care and Use Committee.
4.9. Laser photocoagulation, E3330 intravitreal injection, and
quantiﬁcation of the CNV lesions
Mice were anesthetized by 50 mg/kg ketamine HCl and 10 mg/
kg xylazine. Topical 1% tropicamide, and 2.5% phenylephrine were
administered for pupil dilation. Animals were positioned before a
slit-lamp with a laser-delivery system (Coherent Novus 2000
Argon Laser System, Santa Clara, CA, USA). The fundus was
visualized using a cover slip with Cornea Coats (Hydroxypropyl-
methylcellulose, Insight Instruments Inc., Stuart, FL, USA). Laser
photocoagulation (532 nm wavelength, 100 mW power, 50 μm
spot size, and 0.1 s duration) was performed bilaterally in each
mouse. A series of four laser spots were concentrically placed at
approximately 9, 12, 3, and 6-o'clock positions and 75–100 μm
around the optic disk in each eye. All the laser burns had the
appearance of a cavitation bubble. Right after laser photocoagula-
tion, animals received a single intravitreal injection of 1 μl E3330
in one eye and the same volume of Balanced Saline Solution (BSS,
Akorn Inc., Lake Forest, IL, USA) as a vehicle control in the fellow
eye. Target concentration of E3330 in the retinochoroidal was
approximately 20 μM. Two weeks after laser photocoagulation,
mice were sacriﬁced and eyes were processed for CNV analysis.
Fluorescent labeled isolectin was used to stain CNV spots
according to previous reports [33,80]. Brieﬂy, 4% PFA ﬁxed eyecups
were incubated with blocking solution containing 3% normal
donkey serum, 0.2% Triton x-100 in PBS and then stained with a
1:100 diluted isolectin in blocking buffer at 4 1C overnight. With
4–6 relaxing radial cuts, the RPE-choroid-sclera complex was
ﬂattened and mounted with the RPE side upward. The area of
CNV lesion in each sample was measured using SPOT Advanced
software (Diagnostic Instruments Inc., Sterling Heights, MI, USA).
4.10. Statistical analysis
Results of quantitative studies were expressed as mean7SEM
of at least three independent experiments. Differences were
assessed using one-way analysis of variance (ANOVA) for repeated
measures followed by Fisher's least signiﬁcant difference test
when appropriate. The statistical analyses were performed using
IBM SPSS Statistics 19 (Armonk, NY). A value of poo0.05 was
considered statistically signiﬁcant.
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